在帕金森病中早期检测缺食症迹象:一种基于人工智能的方法,使用非侵入性传感器
Michele Antonio Gazzanti Pugliese di Cotrone1,2, Nidà Farooq Akhtar1,3, Martina Patera2
1Department of Information Engineering, Electronics and Telecommunications, Sapienza University of Rome, 00185 Rome, Italy.
Sensors (Basel, Switzerland)
|November 27, 2025
概括
这项研究使用可穿戴传感器和人工智能来检测帕金森病患者的早期吞问题,甚至在症状出现之前. 非侵入性系统准确地识别了帕金森病患者的微妙肌肉模式差异.
科学领域:
- 生物医学工程 生物医学工程
- 神经科学是一个神经科学.
- 老年学是一门学科.
背景情况:
- 帕金森病 (PD) 通常导致吞障碍 (吞困难).
- 早期发现亚临床吞功能障碍对于管理PD至关重要.
- 目前的诊断方法可能无法识别早期,临床前的吞障碍.
研究的目的:
- 评估一种非侵入性可穿戴传感器系统,用于在老年PD患者中描述吞.
- 检测PD患者在没有临床诊断的吞功能障碍的情况下吞机制的客观差异.
- 评估使用人工智能和传感器数据用于早期检测吞功能障碍的可行性.
主要方法:
- 使用了带有加速度计和高密度表面肌电图 (HD-sEMG) 传感器的可穿戴系统.
- 收集了PD患者和健康对照者的吞数据,使用不同的玻尿酸粘度.
- 应用机器学习 (ML) 和主要组件分析 (PCA) 用于数据处理和主题分类.
主要成果:
- 经过ML分析,成功地将受试者分为两个不同的组,主要是PD患者和对照组.
- 获得了高分类准确度 (83.3%) 和F1得分 (84.5%).
- 鉴定了脑下肌肉激活模式的显著差异,即使在没有临床失足症的PD患者中也是如此.
结论:
- 可穿戴式传感器系统提供了一种可靠的,非侵入性的方法来评估吞功能.
- 这项技术可以帮助早期检测帕金森病的亚临床吞功能障碍.
- 客观地描述吞机制可以改善患者的治疗和治疗结果.
相关概念视频
Neural Regulation
43.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.0K
Parkinson's Disease: Treatment
953
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
953
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K


